Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • News
  • Industry
  • Pharma News
  • Macleods Pharma Wins...

Macleods Pharma Wins Legal Battle Over Linagliptin Patent

Farhat NasimWritten by Farhat Nasim Published On 2025-01-21T17:41:25+05:30  |  Updated On 21 Jan 2025 5:41 PM IST
Cough Syrup Warning Will Not Affect Existing Stock: HC Relief to Glenmark, Zuventus

Delhi High Court

  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

New Delhi: In a major setback to Boehringer Ingelheim, the Delhi High Court has upheld the maintainability of a revocation petition filed by Macleods Pharmaceuticals concerning the Indian Patent IN 243301 for the anti-diabetic drug 'LINAGLIPTIN'.

The judgment, pronounced by Justice Amit Bansal on 15th January 2025, addressed crucial issues concerning the maintainability of a revocation petition when the petitioner has raised a defence of invalidity in a parallel infringement suit and the impact of patent expiration on such petitions.

The dispute centered around Indian Patent IN 243301, registered to Boehringer Ingelheim, for the anti-diabetic drug 'LINAGLIPTIN.' Granted on 5th October 2022 with a priority date of 21st August 2002, the patent expired on 18th August 2023. Macleods Pharmaceuticals, engaged in manufacturing generic pharmaceuticals, filed a revocation petition on 17th February 2022 under Section 64(1) of the Patents Act. This was shortly before its planned commercial launch of a generic version of 'LINAGLIPTIN,' which led to Boehringer Ingelheim filing an infringement suit against Macleods in the Himachal Pradesh High Court.

Boehringer Ingelheim, represented by Senior Counsel, argued that the revocation petition was unnecessary and should be dismissed. Their contention was twofold: first, the defence of invalidity raised by Macleods under Section 107 of the Patents Act in the infringement suit covered similar grounds as the revocation petition, potentially causing conflicting judgments. Second, they asserted that the petitioner ceased to qualify as a 'person interested' under Section 2(1)(t) of the Act post-expiry of the patent, thereby rendering the revocation petition unsustainable.

Macleods Pharma, represented by Counsel, countered that Section 64 provides an independent statutory right to seek revocation of a patent, distinct from the defence of invalidity in an infringement suit. They emphasized that a revocation petition operates in rem, impacting the validity of the patent itself, while a defence under Section 107 is limited to the parties involved. Furthermore, they argued that the expiry of the patent does not nullify the petitioner’s interest, as damages could still be pursued for alleged infringement during the patent’s term.

In its detailed analysis, the Court differentiated the scope and effect of Sections 64 and 107 of the Patents Act. While Section 107 allows invalidity as a defence in infringement suits, adjudicated at the District Court level unless a counter-claim is filed, Section 64 empowers the High Court or the Intellectual Property Appellate Board to revoke a patent entirely, removing it from the Register of Patents. The Court highlighted that these provisions operate independently, allowing parallel proceedings without statutory conflict. It observed;

"The scope and effect of a revocation petition filed under Section 64 of the Patents Act and the defence of invalidity taken under Section 107 of the Patents Act in an infringement suit is entirely different. Hence, the present revocation petition is maintainable."

On the issue of sustainment post-expiry, the Court held that the petitioner’s interest remains valid due to the ongoing infringement suit and the possibility of damages claims. Expiry of the patent does not extinguish the cause of action for revocation, as a finding of invalidity would have significant implications for pending or future claims related to the patent. The court clarified;

"The petitioner in the present case is a person who is interested in manufacture and sale of the patented products and he is also a defendant in the patent infringement suit filed by the respondent no.2. Therefore, the petitioner qualifies as a 'person interested' in terms of Section 2(1)(t) of the Patents Act and it would be entitled to file and maintain the present revocation petition."
"Just because the term of the patent has expired, it would not mean that the suit has become infructuous, as the cause of action, insofar as damages are concerned, still survives. Applying the same rationale, it cannot be argued that a revocation petition cannot be filed or will not survive (if filed earlier) after the term of the patent has expired."

Subsequently, Justice Bansal dismissed the applications filed by Boehringer Ingelheim seeking dismissal of the revocation petition. The Court affirmed the maintainability of the revocation petition and directed that it proceed to be adjudicated on its merits. It held;

"The Himachal Suit filed by the respondent no.2 (Boehringer) is still continuing despite the term of the patent having expired. If the petitioner succeeds in the present petition and the subject patent is revoked, the suit of the respondent no. 2 would be liable to be dismissed. Therefore, there is a valid cause of action in favour of the petitioner to pursue the present petition and simply because the life of the patent has expired, would not mean that the present petition becomes infructuous. Therefore, I am of the opinion that the present petition can be sustained even after the expiry of the subject patent."
"In light of the discussion above, I do not find merit in the objections taken by the respondent no. 2 with regard to the maintainability and sustainability of the present rectification petition. Consequently, both I.A. 7635/2024 and I.A. 46685/2024 are dismissed."

To view the original judgement, click on the link below:

https://indiankanoon.org/doc/83528155/

boehringer ingelheimmacleods pharmaceuticalslinagliptinpatents actamit bansalinfringement suitpatent litigationpharmapharma newslatest pharma newsdiabetesanti-diabeticanti-diabetesdiabetes drugdelhi high courtMacleods news
Farhat Nasim
Farhat Nasim

    Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

    Show Full Article
    Next Story

    Editorial

    Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer - Dr Aditya Murali

    Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer...

    Aspirin in Primary Prevention- When to Consider?

    Aspirin in Primary Prevention- When to Consider?

    Featured image representing medico legal

    What's the Role of Expert Opinion in Medical Negligence?

    7- Point Discharge Protocol for AECOPD: Time to Inculcate in Practice

    7- Point Discharge Protocol for AECOPD: Time to Inculcate in Practice

    Aspirin Use in Women Aged 40-50 with Diabetes and Hypertension: Identifying the Ideal Candidates

    Aspirin Use in Women Aged 40-50 with Diabetes and Hypertension: Identifying the Ideal Candidates

    View All

    Journal Club Today

    Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer - Dr Aditya Murali

    Real-World Case study: Darbepoetin Alfa for Chemotherapy-Induced Anemia in Metastatic Breast Cancer...

    View All

    Health News Today

    Health Bulletin 09/ May/ 2025

    Health Bulletin 09/ May/ 2025

    View All
    © 2022 All Rights Reserved.
    Powered By: Hocalwire
    X
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok